Cognition Therapeutics, Inc. ( (CGTX) ) has released its Q2 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for age-related degenerative diseases and disorders of the central nervous system and retina, utilizing proprietary biology and chemistry platforms. The latest earnings report for the quarter ended June 30, 2025, highlights the company’s ongoing financial challenges, with a net loss of $6.7 million for the quarter and $15.2 million for the first half of the year. Despite these losses, the company continues to advance its lead product candidate, zervimesine (CT1812), and has generated $12.2 million in grant income for the first half of 2025. The company’s cash and cash equivalents decreased to $10.7 million as of June 30, 2025, from $25 million at the end of 2024, reflecting the need for additional funding to support its operations and growth strategy. Cognition Therapeutics remains focused on securing additional capital through public offerings, private placements, and strategic collaborations to sustain its operations and advance its product development pipeline.